-
-
-
-
Manufacturing
-
Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China
ABOUT US
Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China
Release time：
2023-10-12
Qilu Pharmaceutical Co., Ltd. today announced it has received approval in China from the National Medical Products Administration ("NMPA") for its Paliperidone Palmitate Suspension for Injection, 117mg/0.75ml, 156mg/1ml, 234mg/1.5ml.
The launch of Qilu’s Paliperidone Palmitate Suspension for Injection represents the first generic version of Janssen's Invega Sustenna® in China. Invega Sustenna® is a monthly long-acting atypical antipsychotic medication used to treat schizophrenia and schizoaffective disorder.
The availability of Qilu's generic Paliperidone Palmitate Suspension for Injection in China marks a significant milestone in expanding access to this vital medication and underscores Qilu's commitment to providing high-quality affordable healthcare solutions.
In addition to China, Qilu has also filed generic applications with multiple foreign regulatory agencies, including the U.S. FDA. According to IQVIA®, U.S. annual sales for Invega Sustenna® for the 12 months ended August 2023 were $2.44 billion.
Related News
0531-83126666 
wangzhan@qilu-pharma.com 
Tel: +86-531-83127705, 83127704, 83127706, 83127711
Address: 8888 Lvyou Road, High-tech Zone, Jinan, 250104, China
E mail：export@qilu-pharma.com, FDF@qilu-pharma.com